Bulpin joined Millipore Corporation in 2006 as vice-president for the upstream processing business unit and, in January 2012, assumed leadership of the services and solutions business. Following the company's acquisition by Merck, he was appointed to his current position as head of global pharmaceutical chemicals solutions sales. Prior to Merck Millipore, Bulpin worked at Serologicals Corporation in a number of sales and marketing roles both in the U.S. and Europe.
Bulpin succeeds Jean-Paul Mangeolle, who is retiring from the company after 28 years service.
"Andrew brings a wealth of leadership experience and an in-depth understanding of the life science markets," said Robert Yates, president of Merck Millipore. "With a continued focus on helping biopharmaceutical and pharmaceutical manufacturers advance their molecules to market, Andrew has an unprecedented opportunity to evolve the process solutions business."
